Skip to main content

PolyPeptide Group AG (0AAJ.L)

London Stock Exchange Healthcare BiotechnologyView data quality →
38.5Poor

ValueMarkers Composite Index

Top 4%#43,132 of 44,707

DCF data not available

Piotroski
7/9
Strong
Beneish
-3.12
Low Risk
Altman
2.14
Grey Zone
DCF Value
-
N/A
ROIC
1.0%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

PolyPeptide Group AG (0AAJ.L) — VMCI valuation read

0AAJ.L prints VMCI 39/100 inside the Healthcare sector, where the median sits at 50. The 12-point below-median delta is the cleanest single-number summary of PolyPeptide Group AG's composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On 0AAJ.L, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** 0AAJ.L trades at 26.0x earnings, 44% above the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 1.6x is the rate-sensitivity line to watch; that is the risk line for PolyPeptide Group AG on the trailing financials.

0AAJ.L fell 3.6% over the trailing 7 days, with a -18.6% read on a 30-day basis.

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

CEO: Juan Jose Gonzalez1,362 employeesCHwww.polypeptide.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 0AAJ.L’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.